Community Forum top_calendar.gif top_members.gif top_faq.gif top_search.gif top_home.gif    

Go Back   Community Forum > The Internet Medical Journal > Articles
User Name
Password
FAQ Members List Calendar Search Today's Posts Mark Forums Read


Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old September 24th, 2001, 14:48
sysadmin sysadmin is offline
Administrator
 
Join Date: 2001
Posts: 1,085
1999.07.26 Meta-analysis-Mycobacterium avium subsp. paratuberculos in Crohn's Disease

BACKGROUND: There are conflicting reports on the role of Mycobacterium avium subsp. paratuberculosis as an etiological agent of Crohn's disease in humans. An attempt has been made to resolve this conflict by reviewing available scientific data on the detection of M. paratuberculosis from patients with Crohn's disease.

METHODS: The National Library of Medicine (PubMed) databases were reviewed for information on M. paratuberculosis and/or the association of M. paratuberculosis with Crohn's disease between 1990 and 1998. The papers were analyzed using meta - analytic techniques to determine the association of M. paratuberculosis with Crohn's disease.

RESULTS: A total of 727 patients with Crohn's disease were listed in 27 studies between 1990 and 1998. It was observed that 59 % of the studies did not support an etiological role for M. paratuberculosis in Crohn's disease, while 33% concluded that M. paratuberculosis was an etiological agent, and the remaining 7 % of the studies could not draw any conclusion. Between 1990-1998, meta - analysis of the data on Insertion Sequence 900-based polymerase chain reaction suggested that M. paratuberculosis was more likely to be detected in patients with Crohn's disease (Odds ratio 2.35:1). However, the odds of detecting M. paratuberculosis in Crohn's patients was confounded by both geographical location and the year of the study.

CONCLUSIONS: Based on meta analysis of the 20 available peer reviewed scientific papers (458 patients with Crohn's disease, 584 others) that used IS 900 PCR based assays, it is inferred that M. paratuberculosis is not an etiological agent of Crohn's disease.

Jayarao BM, Shreekumar P. A meta-analytic study on the detection of Mycobacterium avium subsp. paratuberculosis from patients with Crohn's Disease. [Online] Available http://www.medjournal.com/ July 26, 1999.

From The Department of Veterinary Science, Pennsylvania State University, University Park, Pennsylvania. Corresponding author: Dr Bhushan Jayarao, 111, Henning Building, The Pennsylvania State University, University Park, PA 16802 - 3500. Tel: 814 - 863 - 5939. Fax: 814 - 863 - 6140. e-mail: bmj3@psu.edu

INTRODUCTION

In 1932, Crohn and co-workers (1) described a chronic disease in human patient's which was characterized by fever, diarrhoea, progressive anemia and loss of weight. The pathological lesions consisting of ulcerative granulomas and fistulas were mainly found in the terminal ileum (1,2). As yet, the cause of Crohn's disease remains unknown, but a multi factorial etiology including environmental, genetic, immunologic, and microbial factors has been suggested (3,4).

Mycobacterium paratuberculosis, the causative organism of Johne's disease in animals has been implicated as one of the etiologic factors of Crohn's disease (2,3). Johne's disease is a chronic enteritis of ruminants. The symptoms consist of diarrhoea, progressive anemia and weight loss. The lesions are usually restricted to the ileum. The pathological lesions, as in Crohn's disease consist of granulomatous inflammation, without caseation necrosis (5).

A possible association between Crohn's and Johne's disease was first described by Chiodini and co-workers (6,7) in 1984, when they isolated a Mycobacterium from 3 out of 14 patients with Crohn's disease, which was later proved to be M. paratuberculosis by DNA-DNA hybridization techniques (8). Since then, M. paratuberculosis has been detected in few cases of Crohn's disease, but the frequency of detection (3 - 15%) has been very low (9). Polymerase Chain Reaction (PCR) studies based on IS900 (hereafter referred to as IS900 PCR), a multi-copy insertion element specific for M. paratuberculosis have also produced contrasting results (2). Despite this, the interest in the association of M. paratuberculosis with Crohn's disease remains high, especially with recent reports that M. paratuberculosis may survive pasteurization (10,11,12). In the US, this is a matter of grave concern since the reported nationwide incidence for Johne's disease is 2.9% (13), with the possibility that estimates may double with newer diagnostic techniques (14).

In this review we have attempted to analyze worldwide data on the detection of M. paratuberculosis in patients with Crohn's disease over the past decade in order to try and determine whether M. paratuberculosis is one of the etiological agents of Crohn's disease.

METHODS

The National Library of Medicine (PubMed) databases were searched for any English language study on M. paratuberculosis and/or the association of M.paratuberculosis with Crohn's disease between 1990 and 1998. In addition, the relevant references cited in the PubMed articles were reviewed also to supplement the PubMed search.

A total of 70 studies on M. paratuberculosis were available and were reviewed, out of which 27 studies (15 - 41) were included for further evaluation as only these studies examined the detection of M. paratuberculosis in Crohn's disease. A study (42) which evaluated paraffin embedded sections of tissue from patients with Crohn's disease was not included, because patient numbers were not specified.

Meta-analytic techniques were used to analyze the papers based on the guidelines suggested by Hunter and co-workers (43). The articles were categorized based on the year of study, geographic location (Europe, USA and Other countries including Japan, New Zealand, Kuwait and Argentina), technique used to detect M. paratuberculosis, and the number of Crohn's and other patients included in the study (Table 1).

Descriptive statistical analysis was conducted using data compiled from 20 papers that employed IS900 PCR- based methods for detection of M.paratuberculosis using Epi Info version 6.0, a word processing, database, and statistical program for epidemiology on microcomputers (44). To reduce bias, confounders were detected, and the data then stratified based on year of study and geographic location. The stratified data set was analyzed to determine the association between M. paratuberculosis and Crohn's disease.

RESULTS

Between 1990 and 1998, there were 70 reported studies on Crohn's disease worldwide, of which 27 studies specifically explored the association of M. paratuberculosis with Crohn's disease.

It was observed that 16 of 27 (59 %) of the studies did not support an etiological role for M. paratuberculosis in Crohn's disease, while 9 of 27 (33%) concluded that M. paratuberculosis was an etiological agent, and the remaining 2 (7 %) of the studies did not draw any conclusion (Table 1). Interestingly, 6 of 12 (50%) of the studies reported between 1990 - 1994 supported an etiological role for M. paratuberculosis, whereas only 2 of 15 (13%) of the studies reported between 1995 - 1998 supported an etiological role for M. paratuberculosis in Crohn's disease.

The techniques used to detect M. paratuberculosis were either DNA based techniques (IS900 PCR) or immunological techniques, primarily Enzyme Linked Immuno Sorbent Assay (ELISA).

Between 1990 - 1998, 20 of 27 (75 %) of the studies utilized DNA based techniques, whereas 7 of 27 (25%) utilized immunological assays for the detection of M. paratuberculosis. Between 1990 - 1994, 7 of 12 (59%) studies utilized DNA based techniques as opposed to 5 of 12 (41%) which used immunological techniques. In comparison most of the studies between 1995 - 1998 (13 of 15 studies, 87%) used DNA based techniques whereas only 2 of 15 (13%) utilized immunological techniques to detect M. paratuberculosis.

Between 1990 - 1998, M. paratuberculosis was detected in 115 of 727 (16%) patients with Crohn's disease. During the same period M. paratuberculosis was detected also in 21 of 335 (6%) cases of ulcerative colitis, 16 of 155 (10%) cases of other inflammatory bowel diseases, and 32 of 603 (5 %) controls (Table 1). Between 1990 - 1994, M. paratuberculosis was detected in 95 of 373 (25%) of patients with Crohn's disease, 6 of 166 (4%) patients with ulcerative colitis, 16 of 54 (30%) patients with other inflammatory bowel diseases, and 18 of 394 (5%) control subjects. As opposed to this, between 1995 - 1998, M. paratuberculosis was detected in 20 of 354 (6%) of patients with Crohn's disease, 15 of 169 (9%) patients with ulcerative colitis, and 14 of 294 (5%) control subjects, but could not be detected in 101 patients with other inflammatory bowel diseases (Table 1).

Between 1990 - 1998, 20 of 27 (74%) of the studies on Crohn's disease were reported from Europe, of which 13 (356 patients with Crohn's disease) were reported between 1990 - 1994, and the remaining 7 (259 patients with Crohn's disease) were reported between 1995 - 1998. It was observed that 7 of 14 (50%) of the studies from Europe between 1990 - 1994 supported an etiological role for M. paratuberculosis, whereas only 1 of 7 (14 %) of the studies between 1995 - 1998 supported an etiological role for M. paratuberculosis in Crohn's disease.

There were 3 studies on Crohn's disease from the USA (32 patients with Crohn's disease), all of which were reported between 1995 - 1998. Only 1 of 3 (33%) of the studies supported an etiological role for M. paratuberculosis in Crohn's disease.

Between 1990 - 1998, there were 4 studies (80 patients with Crohn's disease) on Crohn's disease from other countries including New Zealand, Kuwait, Japan and Argentina. Except for the study from Argentina (17 patients with Crohn's disease) which was reported in 1994, the other 3 studies were reported between 1995 - 1998. One study from New Zealand was inconclusive, but the remaining 3 (75%) studies failed to support an etiological role for M. paratuberculosis in Crohn's disease.

Sub-analysis of IS900 PCR studies to detect Mycobacterium paratuberculosis in patients with Crohn's disease

Studies have shown that IS 900 PCR-based detection methods have a higher sensitivity and 100% specificity for detection of the presence of M. paratuberculosis DNA in tissue samples. 2, 15, 30 With regard to this review, it was evident that nearly 75% of the investigators had employed IS 900 PCR-based assays for detection of M. paratuberculosis in Crohn's patients. These two important factors led to the selection of the data set that used IS 900 PCR-based detection method for conducting descriptive statistical analysis of the subjects included in these investigations.

Crohn's disease

Between 1990 and 1998, M. paratuberculosis was detected from a significantly higher number of patients with Crohn's disease studied worldwide (odds ratio 2.35:1) or from Europe (odds ratio 4.52:1) (Table 2). During the same period, there were no significant differences in the detection of M. paratuberculosis from patients with Crohn's disease from the United States or other countries (New Zealand, Kuwait, Japan). Between 1990 - 1994, it was evident that M. paratuberculosis was detected from a significantly higher number of patients with Crohn's disease worldwide (odds ratio 5.77:1) or from Europe (odds ratio 5.77:1), but during the same period no studies were reported from USA or other countries. Between 1995-1998, there were no significant differences in the detection of M. paratuberculosis from patients with Crohn's disease as compared to those with ulcerative colitis, other inflammatory bowel diseases or controls, either worldwide, or from any specific geographic location (Table 2).

A plot of the annual percentage of patients with Crohn's disease detected with M. paratuberculosis showed that the worldwide pattern of detection of M. paratuberculosis closely paralleled the pattern of detection of M. paratuberculosis in patients with Crohn's disease from Europe (Fig 1).

Ulcerative colitis

Between 1990 and 1998, Mycobacterium paratuberculosis was detected from a significantly lower number of patients with ulcerative colitis studied worldwide or from Europe (odds ratio 0.17). During the same period there were no significant differences in the detection of M. paratuberculosis from patients with ulcerative colitis from other countries (New Zealand, Kuwait, Japan), while the odds ratio from USA could not be calculated because there were too few patients. Between 1990 - 1994, M. paratuberculosis was detected from a significantly lower number of patients with ulcerative colitis worldwide (odds ratio 0.17), or from Europe (odds ratio 0.17), while no studies were reported from USA or other countries. Between 1995 - 1998, there were no significant differences in the detection of M. paratuberculosis from patients with ulcerative colitis worldwide, or from the group of other countries (Table 2). During the same period, M. paratuberculosis was not detected from any patient with ulcerative colitis studied from Europe, while the odds ratio for USA could not be calculated since there were too few subjects.

Other inflammatory bowel diseases

Between 1990 - 1998, M. paratuberculosis was detected from a significantly lower number of patients with other inflammatory bowel diseases (diseases other than Crohn's disease or ulcerative colitis) from the group of other countries (New Zealand, Kuwait, Japan; odds ratio 0.0). During the same period there were no significant differences in the detection of M. paratuberculosis from patients with other inflammatory bowel diseases worldwide, or from Europe, while the odds ratio for USA could not be calculated since there were too few subjects (Table 2). Between 1990 - 1994, there were no significant differences in the detection of M. paratuberculosis from patients with other inflammatory bowel diseases either worldwide, or from Europe, while no studies were reported from USA or other countries. Between 1995 - 1998, the pattern of detection of M. paratuberculosis from patients with other inflammatory bowel diseases was similar to the pattern seen between 1990 - 1998, except that during this period M. paratuberculosis was not detected from any patient with other inflammatory bowel diseases from Europe.

Controls

Between 1990 and 1998, Mycobacterium paratuberculosis was detected from a significantly lower number of healthy controls worldwide (odds ratio 0.59), or from Europe (odds ratio 0.44) or USA. During the same period, there were no significant differences in the detection of M. paratuberculosis from control subjects from other countries (New Zealand, Kuwait, Japan). Between 1990 - 1994, M. paratuberculosis was detected from a significantly lower number of healthy controls worldwide (odds ratio 0.3), or from Europe (odds ratio 0.3), while no studies were reported from USA or other countries (Table 2). Between 1995 - 1998, M. paratuberculosis was detected from a significantly lower number of healthy controls from USA. During the same period, there were no significant differences in the detection of M. paratuberculosis from control subjects worldwide or from other countries, while M. paratuberculosis was not detected from any control subject from Europe.

DISCUSSION

There have been several studies conducted over the past decade to evaluate the role of M. paratuberculosis as an etiological factor in Crohn's disease (15-42). However, conflicting results from different laboratories have confounded the issue (2,3) and the role of M. paratuberculosis in Crohn's disease continues to remain controversial.

Although several excellent reviews (2,3,45) on M. paratuberculosis and Crohn's disease are available, to our knowledge, a specific attempt to collate and statistically evaluate the data over the past decade has not been made. In this review, we have gathered and analyzed all the available data from studies specifically reporting the detection of Mycobacterium paratuberculosis from patients with Crohn's disease from all over the world, between 1990 and 1998.

The data suggested that a larger number of studies failed to support an etiological role for M. paratuberculosis in patients with Crohn's disease between 1990 - 1998. However, it was observed that during this period M. paratuberculosis was detected in a larger number of patients with Crohn's disease than those patients with ulcerative colitis, other inflammatory diseases or control subjects. The data showed also that M. paratuberculosis was detected from patients with Crohn's disease mainly from Europe between 1990 -1994.

To further investigate the apparent geographical bias confounded by the period of study, meta-analysis was conducted on the data from the 20 available IS900 PCR based studies. The IS900 PCR based studies were selected for 2 reasons. Firstly, IS900 PCR based studies are sensitive and highly specific for the detection of M. paratuberculosis (2,15,30). Secondly, a majority (75%) of the studies between 1990 -1998 used IS900 PCR based assays for the detection of M. paratuberculosis in patients with Crohn's disease.

Meta-analysis revealed that between 1990 - 1998, M. paratuberculosis was detected from a significantly higher number patients with Crohn's disease worldwide by IS900 PCR. It was evident that this was mainly because M. paratuberculosis was detected from a significantly higher number of patients with Crohn's disease from Europe, especially between 1990 - 1994. Between 1990 - 1994 there were no studies reported from the USA or other countries using IS900 PCR- based assays for comparison, but a study reported from Argentina 33 during this period that used immunological techniques failed to detect M. paratuberculosis in patients with Crohn's disease.

It is not clear why M. paratuberculosis was detected in a larger number of patients with Crohn's disease from Europe. Researchers have suggested that the variability in detection of M. paratuberculosis in patients with Crohn's disease could be due to environmental or genetic factors, or an interaction between these 2 factors (3,46). Alternatively, there could be a true association of Crohn's disease with areas of high prevalence of Johne's disease, since some studies have suggested that people living in the vicinity of dairy cattle and sheep herds are at higher risk of contracting Crohn's disease (47-49). However, two (47,48) of the three studies provided circumstantial evidence only for an association between Johne's disease and Crohn's disease.

The other hypothesis by Tamboli (49) which suggested that there was a similarity in the distribution of Crohn's disease and Johne's disease was based on a review of patients with Crohn's disease who were 65 or older. However, Crohn's disease affects both the very young as well as elderly people (3,45). Although survival rates of patients with Crohn's disease have increased (4), it is possible that the study by Tamboli (49) may not have included a significant proportion of the younger people with Crohn's disease.

Further, the National Animal Health Monitoring system (50) Dairy' 96 study has reported that there were no significant differences in Johne's disease prevalence in the United States of America related to Geographic region. Therefore if there was an association between M.paratuberculosis and patients with Crohn's disease, there would not be any difference related to geographic location. The author (49) has failed to explain also why Sweden has a high prevalence of patients with Crohn's disease, even though Johne's disease has not been reported from Sweden. In addition, the author has suggested that heavy rains may wash off M. paratuberculosis from the environment into rivers contributing to the dissemination of M. paratuberculosis. If this were true, then regions with high rainfall and Johne's disease should have higher prevalence of Crohn's disease, which has not been reported. All these observations suggest that there is no true overlap of areas with Johne's disease and Crohn's disease.

One of the major findings in our study was that although M. paratuberculosis was detected in a significantly larger number of patients with Crohn's disease between 1990 - 1994, there were no significant differences in the detection of M. paratuberculosis from patients with Crohn's disease between 1995 - 1998, either worldwide, or from Europe, USA or other countries. In fact, M. paratuberculosis was not detected from even a single patient with Crohn's disease from Europe between 1995 and 1998. If there was a true association between Johne's disease and Crohn's disease, M. paratuberculosis should have been detected in a higher number of patients with Crohn's disease during both periods. Therefore, it appears more likely that M. paratuberculosis does not play an etiological role in Crohn's disease.

Investigators who support a role for M. paratuberculosis in Crohn's disease have argued that culturing the organism from tissues of Crohn's patients is extremely difficult, as is the ability to histologically demonstrate the presence of M. paratuberculosis in the affected tissues.9 Some have suggested that detection is difficult because M. paratuberculosis may exist as cell wall deficient spheroplasts in tissues. 35, 39 This argument could be used to justify the difficulty in isolating and culturing M. paratuberculosis from patients with Crohn's disease, but modern methods of PCR using sensitive and specific probes easily overcome these problems (2,15,30).

The reasons for the variability in PCR results between the earlier and latter half of the decade are not fully clear, but the differences in experimental approaches, tissues used and DNA extraction procedures all could contribute to the variability in PCR results (29). Therefore, it appears that controlled longitudinal studies from different geographical locations using standardized DNA isolation and IS900 PCR protocols are needed to investigate the etiological role of M. paratuberculosis in Crohn's disease.

Although the primary aim of the study was to investigate the role of M. paratuberculosis in Crohn's disease, data from other disease categories were evaluated to see whether there was some association of M. paratuberculosis with inflammatory bowel diseases. The analysis revealed that M. paratuberculosis was detected either in a significantly lower number of patients with ulcerative colitis, other inflammatory bowel diseases and control subjects, or that there were no differences between the various groups. Further, M. paratuberculosis was not reported from any of the patients with inflammatory bowel diseases other than Crohn's disease or ulcerative colitis between 1995 - 1998. Therefore, it appears that M. paratuberculosis does not play a significant role in the inflammatory bowel diseases of human subjects.

The sporadic detection of M. paratuberculosis from all categories of intestinal diseases studied as well as from controls supports the concept that M. paratuberculosis may be a commensal or opportunistic pathogen along with other Mycobacteria in human beings (3). In one study (31), all 4 Crohn's patients who were positive for M. paratuberculosis, were positive by PCR for non-specific Mycobacterial DNA as well. Other studies (15,16,22) using PCR probes to non-specific Mycobacterial DNA, e.g the 16S rRNA gene have shown also the presence of Mycobacterial DNA in patients with Crohn's disease, ulcerative colitis and controls.

If M. paratuberculosis is an etiological factor of Crohn's disease, then specific chemotherapy should help in reducing the symptoms. However, studies on the treatment of Crohn's patients with anti-tuberculous chemotherapy have also revealed conflicting results. Some studies have shown a beneficial effect of a combination of rifampicin, ethambutol, isoniazid, and pyrazinamide or clofazamine (51,52). On the other hand a controlled longitudinal study (53) over 5 years using rifampicin, ethambutol, and isoniazid did not show any clinical benefits at all. Even in those studies with a positive response to the anti-tuberculous therapy, there is some confusion as to whether the response was due to a specific therapeutic effect, or the result of anti-inflammatory effects characteristic of several antibiotics (2). A recent in vitro study 54 has suggested that clarithromycin and rifabutin may be the best chemotherapeutic choices for treatment of M. paratuberculosis , but in vivo tests of their efficacy in Crohn's patients need to be evaluated.

 

CONCLUSION

Our review suggests that M. paratuberculosis does not play an etiological role in Crohn's disease. Although M. paratuberculosis may be detected in patients with Crohn's disease, it appears to be a commensal or opportunistic pathogen. Further controlled longitudinal epidemiological studies of patients with Crohn's disease from different geographical locations are required to clarify the exact role of M. paratuberculosis in Crohn's disease.

This review may help clinicians to advise patients with Crohn's disease regarding the probability of detection of M. paratuberculosis, and the potential benefits of undergoing anti-tuberculous chemotherapy.

 

REFERENCES
  1. Crohn BB, Ginsburg L, Oppenheimer GD. Regional ileitis, a pathologic and clinical entity. JAMA 1932; 99:1323 - 1329.
  2. Horowitz EA, Lien EA. Mycobacteria and Crohn's disease Infect Med 1997; 14: 569 - 573.
  3. Thompson DE. The role of Mycobacteria in Crohn's disease. J Med Microbiol 1994; 41:74-94.
  4. Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted county, Minnesota, 1940 - 1993: Incidence, Prevalence, and Survival. Gastroenterol 1998; 114:1161-1168.
  5. Patterson DS, Allen WM, Lloyd MK. Clinical Johne's disease as a protein losing enteropathy. Vet Rec 1967; 81:717 - 718.
  6. Chiodini RJ, van Kruiningen J, Thayer WR, et al. Possible role of Mycobacteria in inflammatory bowel disease: I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29: 1073 - 1079.
  7. Chiodini RJ, van Kruiningen HJ, Merkal RS, et al. Characteristics of an unclassified Mycobacterium species isolated form patients with Crohn's disease J Clin Microbiol 1984; 20: 966 - 971.
  8. Yoshimura HH, Graham DY, Estes MK, et al. Investigation of association of Mycobacteria with inflammatory bowel disease by nucleic acid hybridization. J Clin Microbiol 1987; 25:45 - 51.
  9. Chiodini RJ. Crohn's disease and the Mycobacterioses: a review and comparison of 2 disease entities. Clin Microbiol Rev 1989; 2 (1): 90 - 117.
  10. Chiodini RJ, Hermon-Taylor J. The thermal resistance of Mycobacterium paratuberculosis in raw milk under conditions simulating pasteurization. J Vet Diagn Invest 1993; 5:629 - 631.
  11. Grant IR, Ball HJ, Neill SD, et al. Inactivation of Mycobacterium paratuberculosis in cows milk at pasteurization temperatures. Appl Environ Microbiol 1996; 62:631 - 636.
  12. Millar D, Ford J, Sanderson J, et al. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows milk in England and Wales. Appl Environ Microbiol 1996; 62: 3446 - 3452.
  13. Merkal RS, Whipple DL, Sacks JM, et al. Prevalence of Mycobacterium paratuberculosis in ileocecal lymph nodes of cattle culled in the United States. J Am Vet Med Assoc 1987; 190:676 - 680.
  14. Cocito D, Gilot P, Coene M, et al. Paratuberculosis. Clin Microbiol Rev 1994; 7:328 - 345.
  15. Kallinowski F, Wassmer A, Hofmann MA, et al. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998; 45: 1552 - 1558.
  16. Cellier C, Beenhouwer HD, Berger A, et al. Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gatroenterol Clin Biol 1998; 22:675 - 678.
  17. Chiba M, Fukushima T, Horie Y, Iizuka M, Masamune O. No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease. J Gastroenterol 1998; 33:482 - 487.
  18. Riggio MP, Gibson J, Lennon A, et al. Search for Mycobacterium paratuberculosis DNA in orofacial granulomatosis and oral Crohn's disease tissue by polymerase chain reaction. Gut 1997; 41: 646 - 650.
  19. Al-Shamali M, Khan I, Al-Nakib B, et al. A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Scand J Gastroenterol 1997; 32:819 - 23.
  20. Mishina D, Katsel P, Brown ST, et al. On the etiology of Crohn's disease. Proc Natl Acad Sci USA 1996; 93: 9816 - 9820.
  21. Walmsley RS, Ibbotson JP, Chahal H, Allan RN. Antibodies against Mycobacterium paratuberculosis in Crohn's disease. QJM 1996; 89: 217 - 221.
  22. Dumonceau JM, Van Gossum A, Adler M, et al. No Mycobacterium paratuberculosis found in Crohn's disease using polymerase chain reaction. Dig Dis Sci1996; 41:421- 426.
  23. Cummins RE, Mullins D, Smith LJ, Ford MJ. Metastatic Crohn's disease: a case report. Pediatr Dermatol 1996; 13(1):25-28.
  24. Frank TS, Cook SM. Analysis of paraffin sections of Crohn's disease for Mycobacterium paratuberculosis using polymerase chain reaction. Mod Pathol 1996; 9:32 - 35.
  25. Rowbotham DS, Mapstone NP, Trejdosiewicz LK, et al. Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction. Gut 1995; 37:660 - 667.
  26. Kreuzpaintner G, Das PK, Stronkhorst A, et al. Effect of intestinal resection on serum antibodies to the Mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease. Gut 1995a; 37:61 -366.
  27. Kreuzpaintner G, Kirschner P, Wallner A, et al. Mycobacteria of Runyon groups I, II and IV do not play an aetiological role in Crohn's disease. Eur J Gastroenterol Hepatol 1995b; 7 :1177 - 1182.
  28. Murray A, Oliaro J, Schlup MT, Chadwick VS. Mycobacterium paratuberculosis and inflammatory bowel disease: frequency distribution in serial colonoscopic biopsies using the polymerase chain reaction. Microbios 1995; 83:217 - 288.
  29. Suenaga K, Yokoyama Y, Okazaki K, Yamamoto Y. Mycobacteria in the intestine of Japanese patients with inflammatory bowel disease. Am J Gastroenterol 1995; 90:76 - 80.
  30. Lisby G, Andersen J, Engbaek K, Binder V. Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by a nested primer polymerase chain reaction. Scand J Gastroenterol 1994; 29: 923 -929.
  31. Fidler HM, Thurell W, Johnson NM, Rook GA, McFadden JJ. Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease. Gut 1994; 35: 506 - 510.
  32. Dell'Isola B, Poyart C, Goulet O ,et al. Detection of Mycobacterium paratuberculosis by polymerase chain reaction in children with Crohn's disease. J Infect Dis 1994; 169: 449 - 451.
  33. Morgante P, Lopez B, Barrera L, Ritacco V, de Kantor IN. Humoral response to mycobacteria in patients with Crohn's disease. Medicina (B Aires) 1994; 54: 97 -102.
  34. Wall S, Kunze ZM, Saboor S, et al. Identification of spheroplast - like agents isolated from tissues of patients with Crohn's disease and control tissues by polymerase chain reaction. J Clin Microbiol 1993; 1: 1241 - 1245.
  35. Stainsby KJ, Lowes JR, Allan RN, Ibbotson JP. Antibodies to Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn's disease and control subjects. Gut 1993; 34:371 - 374.
  36. McFadden J, Collins J, Beaman B, et al. Mycobacteria in Crohn's disease: DNA probes identify the wood pigeon strain of Mycobacterium avium and Mycobacterium paratuberculosis from human tissue. J Clin Microbiol 1992; 30: 3070 - 3073.
  37. Elasghier A, Prantera C, Moreno C, Ivanyi J. Antibodies to Mycobacterium paratuberculosis - specific protein antigens in Crohn's disease. Clin Exp Immunol 1992; 90 (3): 503 - 508.
  38. Moss MT, Sanderson JD, Tizard ML, et al. Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues. Gut 1992 ; 33: 1209 - 1213.
  39. Sanderson JD, Moss MT, Tizard ML, Hermon - Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992; 33: 890 - 896.
  40. Ibbotson JP, Lowes JR, Chahal H, et al. Mucosal cell - mediated immunity to Mycobacterial, enterobacterial and other microbial antigens in inflammatory bowel disease. Clin Exp Immunol 1992; 87: 224 - 230.
  41. Brunello F, Pera A, Martini S, et al. Antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig Dis Sci 1991;36: 1741 - 1745.
  42. Rosenberg WMC, Bell JI, Jewell DP. Mycobacterium paratuberculosis DNA cannot be detected in Crohn's disease tissues. Gastroenterology 1991; 100 (suppl):A611. (Abst)
  43. Hunter JE, Schmidt FL, Jackson GB, eds. Meta-Analysis. Cumulating research findings across studies. 1st ed. Sage publications, Beverly Hills,1982.
  44. Dean AG, Dean JA, Coulombier D, Brendel KA et al. Epi Info, Version 6: a word processing, database and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, GA, 1994.
  45. Engstrand L. Mycobacterium paratuberculosis and Crohn's disease. Scand J Infect Dis Suppl 1995; 98:27 - 29.
  46. Rozen P, Zonis J, Yekutiel P, Gilat T. Crohn's disease in the Jewish population of Tel-Aviv-Yafo. Epidemiologic and clinical aspects. Gastroenterol 1979; 76:25-30.
  47. Mayberry JF, Hitchens RN. Distribution of Crohn's disease in Cardiff. Soc Sci Med 1978; 1: 137 - 138.
  48. vanKruiningen HJ, Columbel JF, Cartun RW, et al. An in-depth study of Crohn's disease in two French families. Gastroenterol 1992; 351 - 360.
  49. Tamboli CP. A hypothesis for explaining the geographical distribution of Crohn's disease. Can J Gastroenterol 1996; 10:173-177.
  50. NAMHS. Johne's disease on US operations. USDA:APHIS:VS, CEAH, National Animal Health Monitoring System. Fort Collins, CO 1997; #N245.1097.
  51. Hampson SJ, Parker MC, Saverymuttu SH, et al. Quadruple antimycobacterial chemotherapy in crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther 1989; 3:343-352.
  52. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89:513 - 518.
  53. Thomas GA, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 1998; 42:497-500.
  54. Williams SL, Beth Harris N, Barletta RG. Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis. J Clin Microbiol 1999; 37:304-309

 

TABLE 1 Synopsis of reviewed articles exploring the relationship between Crohn's disease and Mycobacterium paratuberculosis (1990 - 1998).

 

Authors (reference) Country Assay Method Crohn's Ulcerative Colitis Other Controls Comments
Kallinowski et al, 1998 (15) Germany PCR 21 (0) 14 (0) 0 24 (0) Mycobacteria (M. paratuberculosis) do not play a causative role in Chronic Inflammatory Bowel Disease
Cellier et al, 1998 (16) France PCR 47 (0) 27 (0) 0 20 (0) M. paratuberculosis and M. avium subsp. silvaticum do not play a role in Crohn's disease
Chiba et al, 1998 (17) Japan PCR 34 (0) 0 0 17 (0) The study does not support an etiologic significance for M. paratuberculosis in Crohn's disease
Riggio et al, 1997 (18) UK PCR 7 (0) 0 30 (0) 12 (0) The results suggest that M. paratuberculosis may not be a major etiological agent in orofacial granulomatosis or Crohn's disease
Al - Shamali, 1997 (19) Kuwait PCR 10 (0) 6 (0) 21 (0) 0 The findings do not support an etiologic role for M.paratuberculosis in Crohn's disease
Mishina et al, 1996 (20) USA PCR 8 (8) 2 (2) 2 (0) 0 Clinical trials are necessary with anti- M. paratuberculosis therapy in patients with Crohn's disease
Walmsley et al, 1996 (21) UK ELISA 40 (0) 15 (0) 25 (0) 25 (0) The findings make it unlikely that M. paratuberculosis is of primary pathogenic importance in Crohn's disease
Dumonceau et al, 1996 (22) Belgium PCR 36 (0) 13 (0) 0 23 (0) The data do not support a role for M. paratuberculosis in Crohn's disease
Cummins et al, 1996 (23) USA PCR 1 (0) 0 (0) 0 0 M. paratuberculosis was not detected in metastatic Crohn's disease
Frank and Cook, 1996 (24) USA PCR 23 (0) 0 (0) 0 11 (0) The study failed to confirm a role for M. paratuberculosis in Crohn's disease
Rowbotham et al, 1995 (25) UK PCR 68 (0) 49 (0) 0 26 (0) The results do not support the hypothesis that M. paratuberculosis has an etiological role in Crohn's disease
Kreuzpaintner et al,1995 (26) Germany ELISA 17 (0) 10 (0) 20 (0) 0 The findings support a Mycobacterial etiology of Crohn's disease
Kreuzpaintner et al, 1995 (27) Germany Culture 23 (0) 0 (0) 0 23 (0) The findings suggest that Mycobacteria are not involved in the etiology of Crohn's disease but, rather should be considered as environmental opportunists
Murray et al, 1995 (28) New Zealand PCR 9 (2) 15 (2) 3 (0) 12 (0) The low frequency of detection could be explained on the basis of extremely low numbers of M. paratuberculosis or be consistent with a non-etiological role for M. paratuberculosis in IBD
Suenaga et al, 1995 (29) Japan PCR 10 (10) 18(11) 0 16 (14) The results do not support the hypothesis that M. paratuberculosis is involved in the pathogenesis of crohn's disease
Lisby et al, 1994 (30) Denmark PCR 24 (11) 10 (2) 0 28 (3) Whether the presence of M paratuberculosis is connected to Crohn's disease or is a mere coincidence cannot be stated. Further studies are required
Fidler et al, 1994 (31) UK PCR 31 (4) 10 (0) 0 20 (0) Crohn's disease tissues containing granulomata were more likely to amplify M. paratuberculosis specific DNA on PCR. Equivalent number of Crohn's and non-Crohn's tissues amplified non-specific Mycobacterial DNA
Dell - Isola, 1994 (32) France PCR 18 (13) 5 (1) 6 (2) 24 (7) The results appear to support the hypothesis that M. paratuberculosis is involved in the pathogenesis of Crohn's disease
Morgante et al, 1994 (33) Argentina ELISA 17 (0) 23 (0) 14 (0) 86 (0) An increase in antibody levels to M.paratuberculosis and M. tuberculosis was not detected in the sera of the Crohn's patients
Wall et al, 1993 (34) UK PCR 28 (6) 10 (0) 0 13 (0) Six out of 30 cultures were shown to contain DNA from M. paratuberculosis . Cultures from both controls and Crohn's disease were found to contain Mycobacterial DNA of unknown origin
Stainsby et al, 1993 (35) UK ELISA 38 (0) 15 (0) 0 30 (0) There were no differences in antibody levels to M. paratuberculosis in Crohn's disease and control groups
McFadden et al, 1992 (36) UK PCR 2 (1) 0 (0) 0 0 There are too few isolates to speculate about the etiological significance of Mycobacteria and inflammatory bowel disease, but it is reasonable to conjecture that M. paratuberculosis may be responsible for some cases of Crohn's disease
Elasghier et al, 1992 (37) UK ELISA 29 (24) 20 (0) 0 18 (0) Although the exact proportion of affected patients is yet to be defined, the serological results support the view that M. paratuberculosis infection may play an etiological role in Crohn's disease
Moss et al, 1992 (38) UK Culture 18 (6) 5 (0) 0 6 (1) M. paratuberculosis isolated from man exists in a form which hardly replicates in vitro. This is consistent with the involvement of M. paratuberculosis in a proportion of chronic enteritis in man
Sanderson et al, 1992 (39) UK PCR 40 (26) 23 (1) 0 40 (5) The presence of M. paratuberculosis in 2/3 of Crohn's disease tissues but <5% of ulcerative colitis tissues is consistent with an etiological role for M. paratuberculosis in Crohn's disease
Ibbotson et al, 1992 (40) UK LB 20 (0) 5 (0) 0 21 (0) The results do not support a role of Mycobacteria in Crohn's disease, but bacterial-specific T cell-mediated responses require further study.
Brunello et al, 1991 (41) Italy ELISA 108 (4) 40 (2) 34 (14) 108 (2) The data do not support a causal relationship between M. paratuberculosis and Crohn's disease, but some inflammatory disease cases have unexpected positivities for Mycobacterial antibodies
TOTALS 727 (115) 335 (21) 155 (16) 603 (32)

*Figures in parentheses represent the number of cases in which Mycobacterium paratuberculosis was detected; PCR denotes Polymerase chain reaction; ELISA, Enzyme linked Immunosorbent assay; Cro, Crohn's disease; UC, Ulcerative colitis; Oth, Others including Inflammatory bowel diseases other than Crohn's disease or Ulcerative colitis; Con, Controls; LB, Lymphocyte blastogenesis assay

 

TABLE 2 The effect of Period of Isolation and Geographical location on the detection of M paratuberculosis using IS900 PCR based investigations

< 1990 - 1998 > < 1990 - 1994 > < 1995 - 1998 >

1990 - 1998 # of studies # of subjects Odds Ratio (CI) Chi-Square P Value
Crohn's Disease
Worldwide 20 458 2.35 (1.6 - 3.4) 21.72 < 0.001
Europe 13 363 4.52 (2.66 - 7.72) 39.48 < 0.001
USA 3 32 0.92 (0.19 - 4.62) 0.01 0.903
Other Countries 4 63 0.71 (0.31 - 1.61) 0.8 0.370
Ulcerative Colitis
Worldwide 20 207 0.60 (0.35 - 1.02) 4.02 0.045
Europe 13 166 0.17 (0.05 - 0.48) 15.19 < 0.001
USA 3 2 undefined
Other Countries 4 39 2.04 (0.86 - 4.82) 3.18 0.075
Other IBD
Worldwide 20 62 0.43 (0.13 - 1.45) 2.76 0.096
Europe 13 36 0.49 (0.08 - 2.16) 0.96 0.327
USA 3 2 undefined
Other Countries 4 24 0.0 (0.0 - 0.60) 8.25 0.004
Controls
Worldwide 20 315 0.59 (0.38 - 0.92) 5.94 0.015
Europe 13 259 0.44 (0.24 - 0.80) 8.38 0.004
USA 3 11 0.0 (0.0 - 1.14) 4.92 0.026
Other Countries 4 45 1.82 (0.79 - 4.20) 2.39 0.122

 

1990 - 1994 # of studies # of subjects Odds Ratio (CI) Chi-Square Value P Value
Crohn's Disease
Worldwide 7 161 5.77 (3.25 - 10.3) 45.01 < 0.001
Europe 7 161 5.77 (3.25 - 10.3) 45.01 < 0.001
USA 0 0
Other Countries 0 0
Ulcerative Colitis
Worldwide 7 63 0.17 (0.05 - 0.51) 13.77 < 0.001
Europe 7 63 0.17 (0.05 - 0.51) 13.77 < 0.001
USA 0 0
Other Countries 0 0
Other IBD
Worldwide 7 6 1.54 (0.19 - 9.97) 0.25 0.619
Europe 7 6 1.54 (0.19 - 9.97) 0.25 0.619
USA 0 0
Other Countries 0 0
Controls
Worldwide 7 131 0.30 (0.16 - 0.56) 17.13 < 0.001
Europe 7 131 0.30 (0.16 - 0.56) 17.13 < 0.001
USA 0 0
Other Countries 0 0

 

1995 - 1998

# of studies # of subjects Odds Ratio (CI) Chi-Square Value P Value
Crohn's Disease
         
Worldwide 13 297 0.82 (0.44 - 1.53) 0.43 0.51
Europe 6 202 No M para detected    
USA 3 32 0.92 (0.19 - 4.62 0.01 0.903
Other Countries 4 63 0.71 (0.31 - 1.61) 0.80 0.37
Ulcerative Colitis
         
Worldwide 13 144 1.62 (0.82 - 3.17) 2.26 0.133
Europe 6 103 No M para detected    
USA 3 2 undefined    
Other Countries 4 39 2.04 (0.86 - 4.82) 3.18 0.075
Other IBD
         
Worldwide 13 56 0.44 (0.07 - 1.90) 1.35 0.245
Europe 6 30 No M para detected    
USA 3 2 undefined    
Other Countries 4 24 0.0 (0.0 - 0.60) 8.25 0.004
Controls
         
Worldwide 13 184 1.02 (0.51 - 2.02) 0.01 0.942
Europe 6 128 No M para detected    
USA 3 11 0.0 (0.0 - 1.14) 4.92 0.026
Other Countries 4 45 1.82 (0.79 - 4.20) 2.39 0.122

IS900 PCR denotes Insertion Sequence 900 based polymerase chain reaction; CI = Confidence Interval; Other IBD = other inflammatory nflammatory bowel diseases other than Crohn's disease or Ulcerative colitis; M.Para = Mycobacterium paratuberculosis; Other countries include New Zealand, Kuwait and Japan.

Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Statistical analysis in clinical studies: An introduction to fundamentals for physicians rjtheodorou Articles 0 September 13th, 2004 00:04


All times are GMT -8. The time now is 14:15.


Powered by: vBulletin Version 3.0.3
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.



Be careful about reading health books. You may die of a misprint.  
- Mark Twain (1835 - 1910)

We are committed to your good health. That means that while we provide editorial medical information, we must insist that you work with your own doctor in regards to your personal health issues. All content on Medjournal.Com is strictly editorial. It constitutes medical opinion, NOT ADVICE. We do not endorse or recommend the content of Medjournal.com or the sites that are linked FROM or TO Medjournal.com. Use common sense by consulting with your doctor before making any lifestyle changes or other medical decisions based on the content of these web pages. Medjournal.Com and the Internet Medical Journal shall not be held liable for any errors in content, advertising, or for any actions taken in reliance thereon.